Plain-English translation of NCT05242315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
After a liver transplant, patients need to take medications to prevent their body from rejecting the new organ. This trial is testing Envarsus, a new once-daily version of a common anti-rejection drug called tacrolimus. The study wants to see if this medication works just as well as the standard twice-daily version but causes fewer serious side effects, especially kidney problems and tremors.
The standard anti-rejection medication after liver transplant can cause serious side effects—including kidney damage (which happens in about 1 in 4 patients), shaking, and metabolic problems. This medication is designed to deliver the drug more slowly and steadily, which may reduce these harmful side effects while still protecting the transplanted organ.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to take either the new once-daily medication or the standard twice-daily version. You would take your assigned medication exactly as instructed and attend follow-up visits at the University of Alberta to have blood tests and check-ups. The study will monitor your kidney function, blood sugar, tremors, and how well your transplanted liver is working over time.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
Canada